RT Journal Article SR Electronic T1 Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant Insulinomas JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1073 OP 1078 DO 10.2967/jnumed.110.085142 VO 52 IS 7 A1 Damian Wild A1 Emanuel Christ A1 Martyn E. Caplin A1 Tom R. Kurzawinski A1 Flavio Forrer A1 Michael Brändle A1 Jochen Seufert A1 Wolfgang A. Weber A1 Jamshed Bomanji A1 Aurel Perren A1 Peter J. Ell A1 Jean Claude Reubi YR 2011 UL http://jnm.snmjournals.org/content/52/7/1073.abstract AB Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor subtype 2 (sst2) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst2 receptor imaging in the management of malignant insulinoma patients was investigated. Methods: Eleven patients with malignant insulinoma were prospectively included. 111In-[Lys40(Ahx-diethylenetriaminepentaacetic acid [DTPA])NH2]-exendin-4 SPECT/CT, 68Ga- DOTATATE PET/CT, and in vitro receptor autoradiography were performed to assess the receptor status and to evaluate the detection rate. Results: GLP-1 receptor targeting was positive in 4 of 11 patients, and sst2 receptor expression was positive in 8 of 11. In only 1 patient were both receptors expressed. In 1 patient, GLP-1 receptor imaging was the only method that successfully localized the primary tumor in the pancreas. In 3 patients with sst2-expressing tumors, DOTATATE radiotherapy was effectively applied. Conclusion: As opposed to benign insulinomas, malignant insulinomas often lack GLP-1 receptors. Conversely, malignant insulinomas often express sst2, which can be targeted therapeutically.